A comprehensive listing of bioactivation pathways of organic functional groups
…, E Callegari, KR Henne, AE Mutlib… - Current drug …, 2005 - ingentaconnect.com
The occurrence of idiosyncratic adverse drug reactions during late clinical trials or after a
drug has been released can lead to a severe restriction in its use and even in its withdrawal. …
drug has been released can lead to a severe restriction in its use and even in its withdrawal. …
[PDF][PDF] Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine.
GM Bores, FP Huger, W Petko, AE Mutlib… - … of Pharmacology and …, 1996 - researchgate.net
Acetylcholinesterase(AChE) inhibitors from several chemical classes have been tested for
the symptomatic treatment of Alzheimer’s disease; however, the therapeutic success of these …
the symptomatic treatment of Alzheimer’s disease; however, the therapeutic success of these …
Application of stable isotope-labeled compounds in metabolism and in metabolism-mediated toxicity studies
AE Mutlib - Chemical research in toxicology, 2008 - ACS Publications
Stable isotope-labeled compounds have been synthesized and utilized by scientists from
various areas of biomedical research during the last several decades. Compounds labeled …
various areas of biomedical research during the last several decades. Compounds labeled …
Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of …
AE Mutlib, H Chen, GA Nemeth, JA Markwalder… - Drug Metabolism and …, 1999 - ASPET
Efavirenz (Sustiva, Fig. 1 ) is a potent and specific inhibitor of HIV-1 reverse transcriptase
approved for the treatment of HIV infection. To examine the potential differences in the …
approved for the treatment of HIV infection. To examine the potential differences in the …
The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats
AE Mutlib, RJ Gerson, PC Meunier, PJ Haley… - Toxicology and applied …, 2000 - Elsevier
… Efavirenz is metabolized extensively in a species-specific manner including the formation
of a novel cysteinylglycine conjugate (Mutlib et al., 1999a,b). This conjugate results from the …
of a novel cysteinylglycine conjugate (Mutlib et al., 1999a,b). This conjugate results from the …
Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells
…, DA Jackson, P Kulanthaivel, AE Mutlib… - Chemical research in …, 2003 - ACS Publications
Capsaicin is a common dietary constituent and a popular homeopathic treatment for chronic
pain. Exposure to capsaicin has been shown to cause various dose-dependent acute …
pain. Exposure to capsaicin has been shown to cause various dose-dependent acute …
Kinetics of Acetaminophen Glucuronidation by UDP-Glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential Implications in Acetaminophen− Induced …
AE Mutlib, TC Goosen, JN Bauman… - Chemical research in …, 2006 - ACS Publications
The importance of uridine 5‘-diphosphate-glucuronosyltranferases (UGT) 2B15 and other
UGT enzymes (1A1, 1A6, and 1A9) in glucuronidating acetaminophen (APAP) is demonstrated…
UGT enzymes (1A1, 1A6, and 1A9) in glucuronidating acetaminophen (APAP) is demonstrated…
Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone
…, R Kubik, J Hanson, E Urda, AE Mutlib - Toxicological …, 2006 - academic.oup.com
Abstract Treatment with the antidepressant nefazodone has been associated with clinical
idiosyncratic hepatotoxicty. Using membranes expressing human bile salt export pump (BSEP)…
idiosyncratic hepatotoxicty. Using membranes expressing human bile salt export pump (BSEP)…
Application of hyphenated LC/NMR and LC/MS techniques in rapid identification of in vitro and in vivo metabolites of iloperidone.
AE Mutlib, JT Strupczewski, SM Chesson - Drug Metabolism and …, 1995 - ASPET
Iloperidone, 1(-)[4(-)[3(-)[4-(6-fluro-1,2-benzisoxazol-3-yl)-1- piperidinyl]propoxy]-3-methoxyphenyl]ethanone,
is currently undergoing clinical trials as a potential antipsychotic agent. …
is currently undergoing clinical trials as a potential antipsychotic agent. …
A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4 …
…, JR Soglia, J Atherton, L Yu, AE Mutlib… - Chemical research in …, 2007 - ACS Publications
The current study examined the bioactivation potential of a nonpeptidyl thrombopoietin
receptor agonist, 1-(3-chloro-5-((4-(4-fluoro-3-(trifluoromethyl)phenyl)thiazol-2-yl)carbamoyl)…
receptor agonist, 1-(3-chloro-5-((4-(4-fluoro-3-(trifluoromethyl)phenyl)thiazol-2-yl)carbamoyl)…